The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. ... Why Pfizer's Stock Price Isn't Reflecting Its True Value. Feb. 19, 2025 7:22 AM ET Pfizer Inc. (PFE) ...

David Werner, Metro Loft land $135M loan for Pfizer HQ conversion Northwind Group financing NYC’s largest office-to-resi conversion ...